GGrantIndex
← Leaderboards

Jennifer B Marks

University Of Miami School Of Medicine

$6,157,639
Attributed
$6,157,639
Total exposure
7
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $689.6K · FY200515
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15

Funding mix

By agency

NIH$6,157,639 · 7

By mechanism

U01$6,126,902 · 2
M01$30,737 · 5

Top collaborators

No co-investigators on record.

Most similar at University Of Miami School Of Medicine

Same institution · by research overlap

Others in their field

Top investigators on “Insulin

Research focus

InsulinClinical TrialsClinical ResearchAutoimmunityResearch PersonnelSiteStructure Of Beta Cell Of IsletDiabetes MellitusPositioning AttributeOralFuturePreventionCell PhysiologyResponseBaseInsulin SecretionAutoreactive T CellMediatingCellsDesignEnvironmentNatural HistoryPreventSuccess

Grant awards (19)

CLINICAL AFFILIATE OF THE TYPE 1 DIABETES TRIALNET$429,950
U01 · FY2015 · DK · contact PI
CLINICAL AFFILIATE OF THE TYPE 1 DIABETES TRIALNET$614,480
U01 · FY2014 · DK · contact PI
Type 1 Diabetes TrialNet Clinical Center: Effects of Alefacept in New Onset T1D$504,391
U01 · FY2013 · DK · contact PI
Type 1 Diabetes TrialNet Clinical Center: Effects of Alefacept in New Onset T1D$689,584
U01 · FY2012 · DK · contact PI
Type 1 Diabetes TrialNet Clinical Center: Effects of Alefacept in New Onset T1D$680,318
U01 · FY2011 · DK · contact PI
Type 1 Diabetes TrialNet Clinical Center: Effects of Alefacept in New Onset T1D$620,438
U01 · FY2010 · DK · contact PI
Type 1 Diabetes TrialNet Clinical Center: Effects of Alefacept in New Onset T1D$528,583
U01 · FY2009 · DK · contact PI
Diabetes TrialNet$635,236
U01 · FY2007 · DK · contact PI
Diabetes TrialNet$1
U01 · FY2006 · DK · contact PI
Diabetes TrialNet$385,655
U01 · FY2005 · DK
GLYCEMIC CONTROL/COMPLICATIONS TYPE 2 DM MARKERS/MECHANISMS VASCULAR DISEASE$19,127
M01 · FY2005 · RR
TYPE 1 DIABETES TRIALNET-NATURAL HISTORY OF THE DEVELOPMENT OF TYPE 1 DIABETES$683
M01 · FY2005 · RR
METABOLIC ASSESSMENTS IN TYPE I DM TO COMPARE RELIABILITY OF MMTT &IV GLUCAGON$136
M01 · FY2005 · RR
Diabetes TrialNet$264,495
U01 · FY2004 · DK
Carbohydrate /Fat Intake /Cardiovascular Risk with Insul$10,174
M01 · FY2004 · RR
Diabetes Prevention Trial of Type 1 Diabetes$617
M01 · FY2004 · RR
Diabetes TrialNet$255,524
U01 · FY2003 · DK
An Altered Peptide Ligand to Prevent Type 1 Diabetes$263,186
U01 · FY2002 · DK
An Altered Peptide Ligand to Prevent Type 1 Diabetes$255,061
U01 · FY2001 · DK